GlobeNewswire·Nov 6, 2026, 8:00 AM ET

Aligos Therapeutics Reports Recent Business Progress and Third Quarter 2026 Financial Results

Aligos Therapeutics reported third-quarter 2026 business progress & financial results on November 6, 2026.
The Phase 2 B-SUPREME study of pevifoscorvir sodium has completed enrollment with 131 participants in the HBeAg+ cohort & 114 in the HBeAg- cohort.
Topline data for both pevifoscorvir sodium cohorts is expected in late Q3 2027.
Partner Amoytop advanced ASO ALG-170675 into Phase 1 clinical studies in China, with Amoytop funding development costs & holding rights in Greater China.
Aligos cash, cash equivalents, & investments totaled $31.1 million as of September 30, 2026, expected to fund operations into Q1 2027.
Net loss for the three months ended September 30, 2026, was $21.9 million ($2.09 per share), compared to $31.5 million ($3.04 per share) in the prior year.
Research & development expenses decreased to $18.9 million from $23.9 million due to lower third-party costs for the pevifoscorvir sodium trial.
General & administrative expenses increased to $5.9 million from $5.2 million primarily due to higher legal expenses.
Interest & other income was $0.2 million, while the change in fair value of 2023 common warrants resulted in $0.2 million income.
Total revenue for the three months ended September 30, 2026, was $3.2 million, comprising $2.8 million from customers & $0.4 million from licensing agreements.